People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. | — | Biotechnology | Series B | $26.9M | $3.5M | 2023 |
Thomas Jensen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Jensen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Laura Benjamin | 1 | 2 |
| Steve Carchedi | 1 | 2 |
| David A. Roth | 1 | 2 |
| James Cullem | 1 | 1 |
| Gerald G. McLaughlin | 1 | 1 |
| Steen A. Knudsen | 1 | 1 |
| Thomas A. Jensen | 1 | 1 |
| Marie A. Foegh | 1 | 1 |
| Joan G. Brown | 1 | 1 |
| James G. Cullem | 1 | 1 |
| Gerald McLaughlin | 1 | 1 |
| Jens Erik Knudsen | 1 | 1 |
| Joan Brown | 1 | 1 |
| Joseph Vazzano | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.